<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="96">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05159895</url>
  </required_header>
  <id_info>
    <org_study_id>DZ2021E0003</org_study_id>
    <nct_id>NCT05159895</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1, Single-Center, Nonrandomized, Open-label Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dizal Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dizal Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 1, open-label, ADME study with single oral administration of [14C]-DZD9008 in&#xD;
      healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1 study to evaluate the excretion of DZD9008 radioactive dose, the metabolic profile,&#xD;
      pharmacokinetics, safety and tolerability following a single oral administration of&#xD;
      [14C]-DZD9008 in healthy male subjects. The purpose of this study is to investigate ADME&#xD;
      properties of DZD9008 by analyzing blood, urine and feces samples collected during the study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Total Radioactivity (Cum% Dose) Recovered in Urine Relative to the Administered Radioactive Dose</measure>
    <time_frame>Up to 85 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Total Radioactivity (Cum% Dose) Recovered in Feces Relative to the Administered Radioactive Dose</measure>
    <time_frame>Up to 85 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Total Radioactivity Excreted in Urine (Ae [UR])</measure>
    <time_frame>Up to 85 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of Total Radioactivity Excreted in Feces (Ae [Fe])</measure>
    <time_frame>Up to 85 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Administered Radioactive Dose (%Dose) Excreted in Urine for [14C]-DZD9008</measure>
    <time_frame>Up to 85 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Administered Radioactive Dose (%Dose) Excreted in Feces for [14C]-DZD9008</measure>
    <time_frame>Up to 85 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>[14C]-DZD9008</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Single dose of [14C]-DZD9008</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-DZD9008</intervention_name>
    <description>Each subject will receive a total of 100 mg DZD9008 oral suspension containing approximately 1 μCi of [14C] as a single administration</description>
    <arm_group_label>[14C]-DZD9008</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male subjects between 18 and 60 years of age, with body mass index of 18.0 to&#xD;
             30.0 kg/m2. Body weight: ≥55 kg,and ≤ 100 kg.&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead ECG, vital sign measurements, clinical laboratory&#xD;
             evaluations.&#xD;
&#xD;
          -  Regular bowel movements (ie, average production of ≥ 1 or ≤ 3 bowel movements a day).&#xD;
&#xD;
          -  Adhere to specific contraception requirements&#xD;
&#xD;
          -  Creatinine clearance ≥ 90 mL/min/1.73 m2.&#xD;
&#xD;
          -  Aspartate aminotransferase and alanine aminotransferase must be ≤2.5 × upper limit of&#xD;
             normal (ULN) and total bilirubin ≤1.5 × ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, GI,&#xD;
             neurological, respiratory, endocrine, or psychiatric disorder.&#xD;
&#xD;
          -  History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as&#xD;
             judged by the investigator, or history of hypersensitivity to DZD9008, its excipients,&#xD;
             or drugs with a similar chemical structure or class.&#xD;
&#xD;
          -  History of stomach or intestinal surgery history or presence of hepatic or renal&#xD;
             disease or surgical procedure that would potentially alter absorption and/or excretion&#xD;
             of orally-administered drugs (uncomplicated appendectomy and hernia repair will be&#xD;
             allowed; cholecystectomy will not be allowed).&#xD;
&#xD;
          -  Any clinically significant abnormalities in physical examination performed at&#xD;
             check-in, vital signs (supine systolic blood pressure &gt;140 mmHg, diastolic blood&#xD;
             pressure &gt;90 mmHg, and pulse rate ≥100 or ≤35 beats per minute) or clinical laboratory&#xD;
             evaluations as judged by the investigator (or designee).&#xD;
&#xD;
          -  Any clinically important abnormalities in rhythm, conduction, or morphology of resting&#xD;
             12-lead ECG, QTcF interval &gt;450 msec, as judged by the investigator (or designee).&#xD;
&#xD;
          -  A history of additional risk factors for Torsades de pointes (eg, heart failure,&#xD;
             hypokalemia, family history of Long QT syndrome).&#xD;
&#xD;
          -  Positive/reactive results on screening tests for serum hepatitis B surface antigen,&#xD;
             hepatitis C antibody, or human immunodeficiency virus (Appendix 2).&#xD;
&#xD;
          -  Acute illness, surgical procedures or trauma from within 2 weeks before screening&#xD;
             until the first administration of the IMP.&#xD;
&#xD;
          -  Subjects with active malignancy or neoplastic disease in the previous 12 months.&#xD;
&#xD;
          -  Ongoing or planned inpatient surgery, dental procedure, or hospitalization during the&#xD;
             study.&#xD;
&#xD;
          -  Administration of a coronavirus disease 2019 (COVID-19) vaccine in the past 30 days&#xD;
             prior to dosing.&#xD;
&#xD;
          -  Use or intend to use any medications/products known to alter drug AME processes,&#xD;
             including St. John's wort, within 30 days prior to check-in, unless deemed acceptable&#xD;
             by the investigator (or designee).&#xD;
&#xD;
          -  Use or intend to use any prescription medications/products within 28 days prior to&#xD;
             check-in, unless deemed acceptable by the investigator (or designee). Exceptions may&#xD;
             be allowed on a case by case basis as agreed by the investigator and sponsor's medical&#xD;
             monitor if considered not to interfere with the aims of the study.&#xD;
&#xD;
          -  Use or intend to use slow-release medications/products considered to still be active&#xD;
             within 14 days prior to check-in, unless deemed acceptable by the investigator (or&#xD;
             designee).&#xD;
&#xD;
          -  Use or intend to use any nonprescription medications/products including vitamins,&#xD;
             minerals, and phytotherapeutic/herbal/plant-derived preparations, gastric pH&#xD;
             modifiers, and neutralizing antacids within 7 days prior to check-in, unless deemed&#xD;
             acceptable by the investigator (or designee).&#xD;
&#xD;
          -  Subjects will avoid the use of any prescription or nonprescription&#xD;
             medications/products or herbal remedies that are strong/moderate CYP3A inhibitors or&#xD;
             inducers within 28 days prior to check-in through the end of study, unless deemed&#xD;
             acceptable by the Investigator.&#xD;
&#xD;
          -  Subjects will avoid the use of any prescription or nonprescription&#xD;
             medications/products or herbal remedies that are transporter (eg, P-gp) inhibitors or&#xD;
             inducers within 28 days prior to the check-in through the end of study, unless deemed&#xD;
             acceptable by the Investigator.&#xD;
&#xD;
          -  Subjects should avoid the use of proton pump inhibitors from 7 days prior to check-in&#xD;
             through 5 days postdose. For H2-antagonists or antacids, administration will follow&#xD;
             the staggered schedule per protocol.&#xD;
&#xD;
          -  Subjects who received a live or live-attenuated vaccine in the 2 weeks prior to IMP&#xD;
             administration.&#xD;
&#xD;
          -  Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity defined as a compound which has not been approved for marketing)&#xD;
             or participation in any other clinical study (including methodology studies where no&#xD;
             drugs were given) in the past 90 days prior to dosing.&#xD;
&#xD;
          -  Subjects who have participated in any radiolabeled drug studies in the last 12 months&#xD;
             prior to check-in.&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study or any other study&#xD;
             investigating DZD9008 and have previously received DZD9008.&#xD;
&#xD;
          -  History of alcohol abuse or excessive alcohol consumption, defined as &gt; 21 units per&#xD;
             week for males. One unit of alcohol equals 8.5 oz (250 mL) beer, 0.85 oz (25 mL)&#xD;
             liquor, or 2.4 oz (125 mL) wine.&#xD;
&#xD;
          -  Positive urine drug detected at screening, positive urinary alcohol test result or&#xD;
             positive urine drug detected at check-in.&#xD;
&#xD;
          -  History or suspected history of alcoholism or drug/chemical abuse within 2 years prior&#xD;
             to check-in, as judged by the investigator (or designee).&#xD;
&#xD;
          -  Use of tobacco- or nicotine-containing products within 3 months prior to check-in, or&#xD;
             positive cotinine at screening or check-in.&#xD;
&#xD;
          -  Ingestion of poppy seed-, Seville orange-, or grapefruit-containing foods or beverages&#xD;
             within 7 days prior to check-in.&#xD;
&#xD;
          -  Receipt of blood products within 2 months prior to check-in.&#xD;
&#xD;
          -  Donation of blood from 3 months prior to screening, plasma from 2 weeks prior to&#xD;
             screening, platelets from 6 weeks prior to screening, or any blood loss greater than&#xD;
             500 mL during the 3 months prior to screening.&#xD;
&#xD;
          -  Poor peripheral venous access.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Blanchard</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chen</last_name>
    <phone>+86 2161095875</phone>
    <email>Rika.Chen@dizalpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Labcorp Clinical Research Unit, Madison site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blanchard</last_name>
      <phone>608-443-1471</phone>
      <email>john.blanchard@labcorp.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>December 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 15, 2021</last_update_submitted>
  <last_update_submitted_qc>December 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

